WARD RECEIVES YAFFE AWARD
Robert M. Ward, MD, FAAP, FCP, DABCP is the recipient of the 2022 PPA Sumner J. Yaffe Lifetime Achievement Award in Pediatric Pharmacology and Therapeutics. “This award is given annually by the Pediatric Pharmacy Association (PPA) in recognition of significant and sustained contributions toward the improvement of children's health through the expansion of the field of pediatric pharmacology and therapeutics.” The title of his award lecture was “ Improving Pediatric Drug Therapy The Past Guides The Future”.
Dr. Ward is an Emeritus Professor of Pediatrics and adjunct Professor of Clinical Pharmacology, School of Medicine, University of Utah. He graduated Cum Laude from Southern Methodist University with a BS in Chemistry before going to Johns Hopkins University for medical school and then to the University of Minnesota hospitals where he completed his pediatric internship and residency training. Staying in Minnesota he completed combined fellowship training in neonatology and clinical pharmacology, the latter under the mentorship of Bernard Mirkin. Upon graduation he joined the faculty of Hershey Medical Center working with the 2002 PPA Yaffe awardee Chet Berlin before moving to the University of Utah in 1985 where he spent his entire career. From 1997 to 2011 he directed the Pediatric Pharmacology Program at Primary Children's Medical Center of the University of Utah.
Dr. Ward has authored or co-authored over 130 peer-reviewed publications describing his seminal research along with 29 book chapters and 8 editorials/editorial commentaries. He has served on US Food and Drug Administration, National Institutes of Health, Center for Disease Control and Prevention, United States Pharmacopeia, and Institute of Medicine Committees and has mentored multiple trainees. His work focusing on the maternal-placental-fetal unit and drug effects upon the fetus and newborn and his active involvement and chair from 1997–2001 of the American Academy of Pediatrics Committee on Drugs have immensely influenced the practice of neonatal therapeutics. The results of his work have directly benefited the care of premature and full-term infants.
Photo of Drs. Michael Reed (L), Robert Ward (C) and Gil Burckhart (R). Dr Ward is holding the Yaffe award
Dr. Ward remains a vocal and steadfast advocate for issues impacting the health of children, locally, nationally, and internationally. He was instrumental in shaping the Food and Drug Administrations' Modernization Act (FDMA), Best Pharmaceuticals for Children Act (BPCA) and Pediatric Research Equity Act (PREA) legislation and the establishment of the Pediatric Pharmacology Research Unit network (PPRU); He was present at the 1997 signing of FDAMA by then President Bill Clinton.
DARSEY RECEIVES THE HELMS AWARD
Edress Darsey, PharmD, FPPA is the recipient of the 2022 PPA Richard A. Helms Award of Excellence in Pediatric Pharmacy Practice. “The Helms Award recognizes exemplary pediatric patent care, sustained and meritorious contributions to pediatric pharmacy practice, sustained and meritorious contributions to Pediatric Pharmacy Association (PPA), ontributions to education, precepting, and or mentorship, and 5. Contributions of new knowledge (scholarship)”. The title of her award lecture at the annual meeting was “It Takes a Village: Pediatric Drug Development”.
Dr. Darcey currently serves as a Global Pediatric Medical Director/Pediatric Clinical Director for Pfizer Pharmaceuticals. She graduated with her Doctorate of Pharmacy Degree from Mercer University, then completing a clinical pharmacy practice residency at the University of Alabama in Birmingham followed by a specialty residency in clinical pharmacokinetics at Mercer University. On completing her training she spent eight years developing and leading clinical pharmacy services and a pediatric pharmacy residency program at Children's Healthcare of Atlanta. During this time, she researched and published studies on pediatric pharmacokinetics, pain management, and other areas of need. In 2000, she joined Pfizer Pharmaceuticals where she worked on a variety of medical teams until January 2014 when she transferred to help build Pfizer's Pediatric Center of Excellence in the office of the Chief Medical Officer where she holds her current position as a Global Pediatric Medical Director/Pediatric Clinical Director. In this position, Dr. Darcey works internally across many Pfizer medicine teams to provide end-to-end support for pediatric studies, including study protocol development, regulation, pediatric pharmacology, and formulations. In addition, she works externally with Children's Hospitals to build and maintain relationships with a network of major children's hospitals and pediatric research centers in order to facilitate pediatric clinical trial site identification and to optimize clinical trial process execution for investigators and patients.
Dr. Darcey has served on the Board of Directors for The Pediatric Pharmacy Association (PPA) and is the current chair of the Drug Development Committee. She is a member of the American College of Clinical Pharmacology (ACCP) and the American Academy of Pediatrics Section on Advances in Therapeutics and Technology.
REED NAMED JPPT EDITOR-IN-CHIEF
At the PPA annual meeting in Norfolk this May, PPA president Kristin Klein announced the retirement of Dr Stephanie Phelps as JPPT editor-in-chief, a role she has so effectively served for 22 years. Her service and unwavering commitment to the Association and more specifically to the Journal has been truly exceptional. Although she may be ready for full retirement, Stephanie will remain active with the Journal. In his email to PPA membership newly inducted president Mike Chicella noted that “The state of the Journal today is a direct result of Stephanie's unwavering commitment to JPPT and her continuous drive for excellence.”
PPA INDUCTS 4 NEW FELLOWS
On October 1, 2008 the PPA Board of Directors established The Fellows of the Pediatric Pharmacy Association (FPPA) recognition program with the first group of 4 inductees elected in 2009. Since its' inception 53 distinguished individuals have been honored as FPPA inductees. Four additional individuals were inducted as the 2022 FPPA including:
Kelly Matson, PharmD, FPPA
Dr. Matson earned her baccalaureate degree in nutritional sciences from the University of Florida and a Doctor of Pharmacy degree from Purdue University. She further completed a pediatric specialty residency at Children's Hospital Colorado in Denver. Today she is a Clinical Professor at the University of Rhode Island (URI), College of Pharmacy with 20 years of clinical pediatric pharmacy experience. She currently is a preceptor for pediatric pharmacy practice experiences at UMass Memorial Children's Medical Center in Worcester, Massachusetts. At URI, she coordinates an advanced pediatric pharmacotherapy elective course and teaches pediatrics within other required and elective pharmacy practice courses. Her clinical and scholarly interests include judicious antimicrobial use, pediatric immunizations, as well as adolescent substance misuse, childhood obesity, and education of pharmacy students. Dr. Matson has been a member of PPA since 2001 and has served on its Board of Directors. She currently is active in the Academic and Infectious Diseases Special Interest Groups and has served on both the Education and Advocacy Committees. She has contributedas author and reviewer to the Journal of Pediatric Pharmacology and Therapeutics. She is also the faculty advisor for the PediRAMS, URI College of Pharmacy PPA student chapter.
Amy Potts, PharmD, FPPA
Dr.Potts holds a Doctor of Pharmacy (PharmD) from Duquesne University ('94) She completed her PGY1 Pharmacy Practice Residency at Vanderbilt University Medical Center ('00 and her PGY2 Pediatric Specialty Residency ('01) at Monroe Carell Jr. Children's Hospital at Vanderbilt (MCJCHV). She is a Board-Certified Pediatric Pharmacy Specialist. In 2018, she completed the newly established Quality Academy Program at MCJCHV and in 2020 receiving her Master of Management in Health Care from Vanderbilt University. Dr. Potts is currently the Program Director for Quality, Safety, and Education for the Department of Pharmacy at MCJCHV.
Dr. Potts is a Past-President ('13–'14) of the Pediatric Pharmacy Advocacy Group (PPAG) and also served as a member of the Board of Directors.
She has been published as a co-author of the “ASHP–PPAG Guidelines for Providing Pediatric Pharmacy Services in Hospitals and Health Systems” and most recently, as lead author on a CHA collaboration entitled “Safely caring for adult patients in a pediatric hospital during the COVID-19 pandemic: A focus on the medication-use process.”
Michael D. Reed, PharmD, FPPA
Dr. Reed received his BS in Pharmacy and Doctor of Pharmacy degree from the College of Pharmacy, University of Cincinnati. While obtaining his doctorate he concurrently served a clinical pharmacy/clinical pharmacology residency in pediatrics at the Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Dr. Reed is currently Professor Emeritus of Pediatrics, School of Medicine, Case Western Reserve University, Cleveland, OH. Former positions include: Director of the Rainbow Clinical Research Center, Rainbow Babies and Children's Hospital, University Hospitals Cleveland Medical Center (2015–2017); Director of the Rebecca D. Considine Research Institute, Director of the Division of Clinical Pharmacology and Toxicology and Associate Chair, Department of Pediatrics, Children's Hospital Medical Center of Akron (2007–2016), and Professor of Pediatrics, Northeast Ohio Medical University (2008–2016). Prior to 2007 he held clinical and faculty positions at Case Western Reserve University School of Medicine (with tenure) and the University of Virginia, in their Departments of Pediatrics.
Dr. Reed's has authored more than 250 published works describing his original research activities, invited reviews and book chapters. He has served PPA as an Associate Editor of the Journal of Pediatric Pharmacology and Therapeutics and has recently been named Editor. He is also recipient of one of PPAs most prestigious awards – The Sumner Yaffe Lifetime Achievement Award … His research interests have focused on the developmental pharmacology and toxicology of drugs in humans and how these data translated into the design of optimal dosing regimens for use in neonates, infants, children, and adults. He has extensive research experience in the design, implementation, and analysis of pharmacokinetic, pharmacodynamic and pharmacogenomic interrelationships as they relate to the maturing infant, child, and adolescent. Dr. Reed has received numerous awards, served on numerous governmental (e.g., NIH, FDA) and scholarly committees, as an officer for academic/professional organizations
Eloise Woodruff, PharmD, FPPA
Dr. Woodruff received her Bachelor of Pharmacy degree from the Massachusetts College of Pharmacy and Allied Health Sciences-Boston and her Doctor of Pharmacy degree from Shenandoah University in Winchester, VA. Dr. Eloise Woodruff is currently the Clinical Pharmacy Specialist in the Neonatal Intensive Care Unit (NICU) at the Children's Hospital of The King's Daughters (CHKD) in Norfolk, Virginia. She is responsible for covering one of two teams in the level IV NICU. She is also the Experiential Site Coordinator for all students that have a clinical rotation at CHKD. She has been a residency preceptor for all 27 CHKD-trained PGY1 residents and 2-PGY2 Pediatric Critical Care residents and has served as an advisor for several pharmacy resident research projects. Dr. Woodruff was the Co-Investigator for 8 years for the IRB-approved Compassionate Use Study of Omegaven for parenteral nutrition associated liver dysfunction at CHKD. She is a Board Certified Pediatric Pharmacy Specialist. Prior to CHKD, she was the Director of Student Development, Liaison to the Academy of Students of Pharmacy and Coordinator of the Pharmacist Recovery Network at the American Pharmaceutical Association in Washington DC.
Throughout her career, she has been an active member and leader in local, state, and national professional pharmacy organizations levels. She has been a longstanding member of the PPA Education Committee since 2006, contributes to the Webinar Committee, served as the PPA Neonatal Special Interest Group Chair for 2 ½ years, was the PPA Annual Meeting NICU Section Programming Chair. She frequently serves as a manuscript reviewer for JPPT. Dr. Woodruff also completed a 3-year term as Member-at-Large on the PPA Board of Directors ('20) Her research and practice interests include medication safety, respiratory syncytial virus (RSV), NAS, gastroschisis and parenteral nutrition associated liver dysfunction.